Recently, the curtain of the A-share annual report has slowly opened
.
According to Wind data, as of December 14, 45 A-share listed companies have disclosed their 2022 annual report performance forecasts, of which more than seventy percent have reported good
results.
In terms of industries, among the companies with good performance, the pharmaceutical and biological industry performed well, with 6 companies pre-happy, including many newly listed pharmaceutical companies
.
For example, Jardine Jardine Jardine Jardine listed on the Growth Enterprise Market on November 1, the company expects its annual operating income in 2022 to be about 1.
444 billion yuan to 1.
544 billion yuan, a year-on-year increase of about 117.
96% to 133.
06%; The net profit attributable to the shareholders of the parent company is about 351 million yuan to 407 million yuan, a year-on-year increase of about 140.
85% to 179.
67%, according to the data, Jardine Jardine is a manufacturer of medical equipment and consumables products in the field of respiratory health, the company's main products include household non-invasive ventilators, ventilation masks, sleep monitors, high-flow humidified oxygen therapy instruments, and provide respiratory health chronic disease management services
.
Huaxia Ophthalmology, which was listed on the Growth Enterprise Market on November 7, expects that the company's operating income in 2022 will be about 3.
317 billion yuan to 3.
440 billion yuan, a year-on-year increase of about 8.
24% to 12.
26%; It is expected that the net profit attributable to shareholders of the parent company in 2022 will be about 520 million yuan to 560 million yuan, a year-on-year increase of about 14.
31% to 23.
10%.
Huaxia Ophthalmology is a large-scale private medical chain group focusing on ophthalmic specialist medical services, and provides ophthalmic general diagnosis and treatment services
.
It is worth mentioning that while the performance is pre-gratifying, recently, Huaxia Ophthalmology has also received the attention of institutions, the company said in the survey of CICC, Bosera Fund and other institutions that the number of loss-making hospitals in the group is expected to drop to a single digit next year, and it is confident that all hospitals will turn losses into profits
by 2024.
In the next 3-5 years, we will strive to achieve a profit growth rate
of 30%.
Dongxing Medical, listed on the Growth Enterprise Market of the Shenzhen Stock Exchange on November 30, expects a net profit of 110 million yuan to 115 million yuan after deducting non-recurring profits and losses from January to December 2022, an increase of 6.
46% to 11.
3% over the previous year; It is expected that the net profit attributable to shareholders of listed companies from January to December 2022 will be 120 million yuan to 130 million yuan, an increase of 8.
84% to 17.
91%
over the previous year.
It is reported that Dongxing Medical is mainly engaged in the research and development, production and sales
of surgical medical devices represented by stapler.
At the beginning of its establishment, the company was mainly engaged in the agency business of medical equipment and consumables, and through endogenous development and epitaxial mergers and acquisitions, it has now developed into a minimally invasive surgical medical device company
represented by stapler.
In addition to the above-mentioned pharmaceutical companies, Chuanning Biotechnology, which opened its application on December 16, expects a net profit attributable to shareholders of listed companies from January to December 2022 of 382 million yuan to 411 million yuan, an increase of 243% to 269%
over the previous year.
The company said that as the sales price of the company's main products remained high, the operating performance showed a steady growth trend
.
Of course, there are good and bad news, and the performance of some pharmaceutical companies in 2022 is relatively average
.
For example, Chenguang Medical, which was listed on the Beijing Stock Exchange on December 7, expects a net profit of 20.
4881 million yuan to 24.
4243 million yuan from January to December 2022, a year-on-year change of -12.
23% to 4.
63%; It is expected that the net profit profit after deducting non-recurring profit and loss from January to December 2022 will be 17.
4969 million yuan to 21.
4332 million yuan, a year-on-year change of -15.
28% to 3.
78%.
However, Chenguang Medical performed well on the first day of listing, rising more than 50%
intraday.
According to the data, Chenguang Medical is an independent innovative enterprise dedicated to the research and development, production and sales of special magnets in the field of medical imaging MRI equipment and high-tech cutting-edge fields, covering superconducting magnetic resonance RF detectors, high-uniformity superconducting magnets, gradient coils, RF amplifiers, gradient amplifiers and other magnetic resonance hardware equipment, and is an independent third-party core hardware supplier
of China's MRI equipment industry chain.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
